![NUVAXOVID<sup>TM</sup>▼ (SARS-CoV-2 rS [NVX-CoV2373]) SUSPENSION FOR INJECTION](/sites/eua/files/images/au-logo.svg){kind=logo}
DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Australia ONLY.
Information about the NUVAXOVIDTM▼ (SARS-CoV-2 rS [NVX-CoV2373]) SUSPENSION FOR INJECTION
This vaccine has provisional registration in Australia for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older as a primary series, 2 dose course or as a booster dose in individuals 18 years of age and older, 6 months after the completion of a primary series. The use of this vaccine should be in accordance with official recommendations.
Important information
Report an Adverse Event (AE)
To report adverse event contact the Therapeutic Goods Administration (TGA) via their adverse event reporting site www.tga.gov.au/reporting-adverse-events.
Alternatively, adverse events can be reported to Novavax Pharmacovigilance at +61 2 7202 1444 or via the Novavax Adverse Event Reporting Form.
Contact Us
Tel: +61 2 7202 1444
09:00 - 17:00
Monday - Friday